BioPharmSignal logoBioPharmSignal

Biotech News

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Harmony Biosciences (HRMY)Harmony BiosciencesEarnings

WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026 Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026 PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Jul.

Related news

HRMYHarmony Biosciences2026-07-21 12:05 EST

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

HRMYHarmony Biosciences2026-08-04 11:30 EST

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

NBIXNeurocrine Biosciences2026-07-09 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-07-30 20:01 EST

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

NGENNervGen Pharma2026-05-18 11:15 EST

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

XENEXenon2026-08-06 20:01 EST

Xenon Reports Q2 2026 Financial Results and Provides Business Update

PRAXPraxis Precision Medicines2026-08-06 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-08-06 11:00 EST

Xeris Biopharma Reports Second Quarter 2026 Financial Results

ALKSAlkermes plc2026-07-28 11:00 EST

Alkermes plc Reports Second Quarter 2026 Financial Results

View all latest news

Harmony Biosciences

Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling. WAKIX Franchise WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the...

Recent company news

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

HRMYHarmony Biosciences2026-08-04 11:30 EST

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

HRMYHarmony Biosciences2026-07-21 12:05 EST

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

HRMYHarmony Biosciences2026-07-16 12:30 EST

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

HRMYHarmony Biosciences2026-06-11 12:05 EST

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Stock data

Close
38.75 USD
Market cap
1.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States